PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
In My Kitchen is a platform that aims to bring together a network of professional and semi-professional chefs to sell their signature dishes and recipes online. The platform was founded in July 2020. In My Kitchen asserts that its business model holds precedence in a time where takeaways have grown in popularity in the UK because of COVID-19. It gives many chefs who have become unemployed or have fewer shifts for developing their creativity and skills whilst allowing them to earn through the gig-economy. The company has a network of more than 70 chefs across London, with backgrounds across a range of cuisines. With the investment received, the company will develop its team and company infrastructure.
days to go:
Expired
investment:
Withheld
Garbanzo Snacks is a profitable businesses, currently selling their chickpeas with a sprinkling of flavour in 725 Holland and Barrett stores. They use 100% chickpeas with minimal processing, this keeps the products as pure and unadulterated as possible.
days to go:
Expired
investment:
Withheld
Run3D is a biotechnology company that has developed a 3D gait analysis system with the aim to help people identify injuries, deliver better performance, and make better running decisions. 3D gait analysis involves using infrared cameras to track positions of small reflective markers attached to a person in motion, capturing measurable data to help quantify a person's risk of injury, biomechanical efficiency, performance, footwear, and recommend proper diagnosis where necessary. The company plans to use the investment to grow its business.
days to go:
Expired
investment:
Withheld
Synergy Grill have developed a grill that cuts gas bills by 50% because air is injected into the combustion. There is also no fat tray with the Synergy Grill, the fat is entirely vapourised and goes back through the food to further enhance the taste.
days to go:
Expired
investment:
£765,000
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics.
Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
days to go:
Expired
investment:
£250,000
Active Food Systems, trading as Synergy Grill, has developed and patented innovative and commercial cooking technology for the food and hospitality industry. Its ‘Fat Atomising Grill' makes cleaning quick and easy while delivering cost savings through a 59% reduction in fuel consumption. The company has sold 2000+ units of the grill to entities like Whitbread, Greene King, Marriott, Radisson and Marstons among others. Synergy Grill asserts that its performance in the first half of the year has been profitable despite COVID-19. They have contracts with reputed organisations like Whitbread and Marstons have generated revenues of £970,000. The company is in conversation with over 50 pubs and restaurants including product trials with Nandos, Weatherspoons and Mitchell Butler that are interested in its product. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£316,488
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go:
Expired
investment:
Withheld
